OCS Stock Overview
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oculis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,630.00 |
| 52 Week High | US$1,850.00 |
| 52 Week Low | US$1,610.00 |
| Beta | 0.082 |
| 1 Month Change | -4.12% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCS | IS Pharmaceuticals | IS Market | |
|---|---|---|---|
| 7D | -1.8% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how OCS performed against the IS Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how OCS performed against the IS Market.
Price Volatility
| OCS volatility | |
|---|---|
| OCS Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in IS Market | 0% |
| 10% least volatile stocks in IS Market | 0% |
Stable Share Price: OCS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OCS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Fundamentals Summary
| OCS fundamental statistics | |
|---|---|
| Market cap | Kr68.72b |
| Earnings (TTM) | -Kr9.23b |
| Revenue (TTM) | Kr137.31m |
500.5x
P/S Ratio-7.4x
P/E RatioIs OCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCS income statement (TTM) | |
|---|---|
| Revenue | CHF876.00k |
| Cost of Revenue | CHF33.96m |
| Gross Profit | -CHF33.08m |
| Other Expenses | CHF25.80m |
| Earnings | -CHF58.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | -3,776.14% |
| Net Profit Margin | -6,721.46% |
| Debt/Equity Ratio | 0% |
How did OCS perform over the long term?
See historical performance and comparison